TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Cytiva BioProcess R&D AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,139,136
|
1,152,452
|
1,528,690 |
| Financial expenses |
334
|
0
|
1,037 |
| Earnings before taxes |
354,189
|
542,696
|
889,799 |
| EBITDA |
1,089,256
|
1,105,284
|
1,481,410 |
| Total assets |
2,165,273
|
3,329,695
|
3,182,048 |
| Current assets |
814,894
|
1,346,013
|
1,183,650 |
| Current liabilities |
1,082,062
|
1,283,352
|
2,055,895 |
| Equity capital |
1,083,212
|
2,046,342
|
1,036,457 |
| - share capital |
9
|
9
|
9 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
50.0%
|
61.5%
|
32.6% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
31.1%
|
47.1%
|
58.2% |
| Return on assets (ROA) |
16.4%
|
16.3%
|
28.0% |
| Current ratio |
75.3%
|
104.9%
|
57.6% |
| Return on equity (ROE) |
32.7%
|
26.5%
|
85.9% |
| Change turnover |
25,863
|
-380,688
|
199,980 |
| Change turnover % |
2%
|
-25%
|
15% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.